论文部分内容阅读
目的:探讨吉非替尼对不同性别晚期非小细胞肺癌(NSCLC)患者的疗效和安全性。方法:选择化疗失败的晚期NSCLC患者74例,分为女性组(36例)和男性组(38例),应用吉非替尼进行单药治疗,口服剂量为250 mg/d。分析两组治疗疗效和安全性。结果:女性组和男性组的总有效率(47.2%vs 26.3%,P=0.062)以及中位无进展生存期(7.9个月vs 5.7个月,P=0.093)差异均无统计学意义;而其中女性腺癌患者的有效率(53.8%)与以及中位无进展生存期(10.1个月)明显优于男性鳞癌患者,差异均有统计学意义,P值均<0.05。两组的不良反应相似主要为皮疹和腹泻。结论:对于晚期NSCLC患者,在无检测表皮生长因子受体(EGFR)情况下,合理选择优势人群,应用分子靶向药物吉非替尼治疗,疗效较高,能有助于提高NSCLC临床个体化治疗水平。
Objective: To investigate the efficacy and safety of gefitinib in patients with advanced non-small cell lung cancer (NSCLC) of different genders. Methods: Seventy-four patients with advanced NSCLC who failed chemotherapy were enrolled in this study. They were divided into female group (36 cases) and male group (38 cases). Gefitinib was given monotherapy. The oral dose was 250 mg / d. Analysis of two groups of treatment efficacy and safety. Results: The total effective rate (47.2% vs 26.3%, P = 0.062) and median progression-free survival (7.9 months vs. 5.7 months, P = 0.093) in the female and male groups were not statistically significant The effective rate (53.8%) and median progression-free survival (10.1 months) of female adenocarcinoma patients were significantly better than those of male squamous cell carcinoma patients, the differences were statistically significant (P <0.05). Adverse reactions in both groups were similar mainly to rash and diarrhea. CONCLUSIONS: For patients with advanced NSCLC, the detection of epidermal growth factor receptor (EGFR) in the absence of reasonable choice of the dominant population, the use of molecular targeted drug gefitinib treatment, a higher efficacy, can help improve the clinical individualized NSCLC Treatment level.